vadimezan has been researched along with az 960 in 1 studies
Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (az 960) | Trials (az 960) | Recent Studies (post-2010) (az 960) |
---|---|---|---|---|---|
272 | 16 | 101 | 14 | 0 | 12 |
Protein | Taxonomy | vadimezan (IC50) | az 960 (IC50) |
---|---|---|---|
Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.003 | |
Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.009 | |
LIM domain kinase 1 | Homo sapiens (human) | 0.2267 | |
LIM domain kinase 2 | Homo sapiens (human) | 4.2784 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 other study(ies) available for vadimezan and az 960
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |